LSE - Delayed Quote GBp

Oxford Biomedica plc (OXB.L)

337.50
-6.00
(-1.75%)
At close: June 9 at 5:14:03 PM GMT+1

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.
NameTitlePayExercisedYear Born
Dr. Frank Mathias CEO & Director 1.11M -- 1962
Dr. Lucinda Crabtree Ph.D. CFO & Director 512.42k -- 1979
Mr. Thierry Cournez Chief Operating Officer -- -- --
Ms. Sophia Bolhassan Head of Investor Relations -- -- --
Ms. Natalie Louise Walter General Counsel & Company Secretary -- -- 1973
Ms. Lisa Doman Chief People Officer -- -- --
Dr. Kyriacos Mitrophanous Ph.D. Chief Innovation Officer -- -- --
Ms. Kati Hudson Head of Intellectual Property and Contracts -- -- --
Dr. Sebastien Ribault Chief Business Officer -- -- --
Mr. Mark Caswell Site Head of UK Operations -- -- --

Oxford Biomedica plc

Windrush Court
Transport Way
Oxford, OX4 6LT
United Kingdom
44 1865 783 000 https://www.oxb.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
850

Description

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Corporate Governance

Oxford Biomedica plc’s ISS Governance QualityScore as of June 1, 2025 is 9. The pillar scores are Audit: 8; Board: 4; Shareholder Rights: 1; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

April 9, 2025 at 6:00 AM UTC

Oxford Biomedica plc Earnings Date

Recent Events

Related Tickers